Method of rectal cancer treatment

FIELD: medicine.

SUBSTANCE: testosterone is introduced intramuscularly and applied on the stomach and breast skin to ensure the steady high blood concentration. 6-8 hours prior to a session of gamma-ray teletherapy, a composite is introduced through rectum. The composite contains sodium alginate, dimethyl sulphoxide solution and testosterone. 6-8 hours later, the composite is removed from rectum. It is followed with gamma-ray teletherapy with "РОД" 5 Gy and local microwave hyperthermia.

EFFECT: method allows enhancing radio modifying treatment effect, inhibiting growth and metastasis of the tumour to the extent of regression, reducing number of by-effects and contraindications.

2 cl, 2 tbl, 1 ex

 

The invention relates to the field of medicine and more specifically to methods of combination therapy of malignant tumors, and can be used in the treatment and prevention of cancer, in particular colorectal cancer.

There is a method of combined treatment of rectal cancer, including local radiomodifying of tumor cells with subsequent radiotherapy and radical surgery, characterized by the fact that local radiomodifying performed by endovascular perfusion its tissue 5%solution of metronidazole through the upper rectal artery when verhneamudarya colorectal cancer, upper rectal and from the internal iliac arteries in the medium and nizhneamudarya rectal cancer with occlusion of these vessels nasirudeen radiopaque emboli, see patent RU No. 2269341, CL A61N 5/10, published 2006.02.10. The method allows to enhance the damaging effect of radiation exposure on radioresistant cancers of the rectum.

There is a method of treatment of colorectal cancer, including the effects on the tumor in the preoperative period remote gamma-irradiation, oral administration involving capecitabine, introduction vnutriuretrale rectum metronidazole in the form of a composite mixture of metronidazole, sodium alginate and dimethyl sulfoxide with p the following operative intervention, while the patient performed a session of remote gamma-therapy GENUS 5 gray on the background of double reception capecitabine, see patent RU No. 2311909, CL A61N 5/10, published 2007.12.10. The invention allows to reduce the frequency locoregional recurrence and metastases and prolongs relapse-free period. The disadvantage of these known methods of treatment of rectal cancer is the lack of effectiveness of the treatment is associated with risk of recurrence and distant metastasis, as well as the technical difficulties that arise when dealing with metronidazole.

There is a method of treatment of rectal cancer by affecting the tumor in the preoperative period remote gamma-irradiation, local microwave hyperthermia and introduced into the intestine of metronidazole in the form of a composite mixture, mainly under the following ratio of ingredients, wt.%: metronidazole 12-22, sodium alginate 4-6, dimethylsulfoxide 2, distilled water to 100, with the implementation of the method the patient conduct a 5-day course sessions remote gamma-therapy GENUS-5 Gr with the introduction of vnutriuretrale composite mixture and holding of the sessions of the local microwave hyperthermia, see patent RU No. 2234318, CL A61N 5/10, published 2004.08 20. This method enables efficient combined treatment of patients with primary resectable cancers of the rectum, to reduce frequent is the occurrence locoregional recurrence and to increase life expectancy and 5-year survival of patients. This method was adopted as a prototype as the closest to the technical essence and the achieved result is similar.

The disadvantage of the prototype and all these known methods of treatment of rectal cancer is a low degree of radiological of the tumor tissue, achieved in its implementation, which is a consequence of the use of metronidazole as the main radiomodifying with a low degree of selective accumulation in tumor tissue. Furthermore, the method of treatment of colorectal cancer according to the prototype has severe side effects associated with organoleptic properties, irritant chemical action of the drug on the mucous membrane of the gastrointestinal tract and neurotoxicity.

Achievable technical result is

- increase radiomodification effect in the implementation of treatment,

- inhibition of growth and metastasis of the tumor until its regression

fewer side effects and contraindications.

Thus, the proposed method can improve the effectiveness of treatment and prevention of cancer, to expand the scope of application of the method. In the proposed method to preserve all the positive properties of the prototype, namely the integrated approach, the properties of the config combined method of treatment of colorectal cancer.

The method is as follows.

Perform daily administration intramuscularly and by applying onto the skin of the abdomen and chest hormonal drug to achieve sustainable higher levels of the sex hormone in the blood. The hormonal drug use testosterone.

Testosterone is the primary male sex hormone, which is secreted in the male sex glands, the testes, and in small quantities by the adrenal cortex in both sexes. Biological action of testosterone manifests itself in the most specific target tissues, where its selective accumulation, mainly to such tissues are cells of the organs of the reproductive system. In clinical practice using synthetic drugs: testosterone propionate, methyltestosterone.

To accelerate the penetration of the drug into the body apply them rubbing into the skin. In parallel, the drugs intramuscularly. The preparations thus impose daily 3-4 ml Total dose and duration of treatment depend on changes in the composition of blood and continues to achieve sustained high levels of hormone-testosterone. In the blood serum of a patient suffering from cancer, determine the content of the main hormones, they may use standard and well known methods.

the and 6-8 hours prior to the session remote gamma-therapy exercise vnutriuretralnami introduction composite mixture including the hormonal drug, as a hormonal drug use testosterone.

Optimal, from the point of view of achievement of the specified technical result is input vnutriuretrale composite mixture, which contains a hormonal drug, sodium alginate and dimethylsulfoxide at the following ratio of ingredients, wt.%: hormonal drug 4-10, sodium alginate 8-12, dimethylsulfoxide 3-5, distilled water to 100.

After 6-8 hours the mixture is removed from the rectum cleansing enema, perform remote gamma-therapy with local microwave hyperthermia (temperature 42,5-43°C for 60 minutes).

Based on the evaluation results of irradiation decide on further treatment. If necessary courses of therapy again. 24-48 hours after the completion of preoperative irradiation, if necessary, perform a radical surgical intervention, the nature and extent of which is determined by the level of localization of the tumor in the rectum and the degree of its local distribution.

The basis of the invention is supposed original technical solution used as radiomodification agent that increases the sensitivity of tumors to ionizing radiation, hormonal drug instead of chemical compounds. The authors of the invention have uni the material properties of sex hormones, which happens when the application of the combined method of treatment of colorectal cancer, particularly in the preoperative period at the stage of radiation therapy and microwave hyperthermia.

The possibility of the method of treatment of colorectal cancer confirmed by research.

The study of the influence of hormonal drug sensitivity of the tumor to distant gamma-therapy GENUS-5 Gr session with local microwave hyperthermia was carried out on laboratory animals inoculated with solid Ehrlich carcinoma line ELD. Animals mice of BALB/C males weighing 20-22 g Cells of Ehrlich carcinoma line ELD instilled mice in the leg muscle of the 7 days before irradiation. The day before irradiation the animals entered testosterone (Testosterone propionate 5%). Local microwave hyperthermia was performed by heating the limb with a growing tumor at a temperature of 43°C for 60 minutes. On the day of irradiation diameter shank with a growing tumor ranged between 7-9 mm (the diameter of the tibia in mice without grafted tumor is in the middle of about 4 mm). Each experimental group consisted of 6-8 animals Irradiation occurred on cobalt gamma setting AGATE-R, equipped with an additional device for increasing the difference in dose rate between the irradiated tumor and shielded by the body of the animal. The dose was equal to 5 Gr.

Animals with LiveTime tumors on the day of exposure were divided into the following groups:

- control group, no effects;

- remote gamma-therapy GENUS-5 Gr (Reg) tumors;

- remote gamma-therapy GENUS-5 Gr (Reg) tumors in combination with local microwave hyperthermia (HT) (Reg + GT);

- remote gamma-therapy GENUS-5 Gr (Reg) tumor on the background of the introduction of radiomodification hormonal drug testosterone (Testosterone + Region),

- remote gamma-therapy GENUS-5 Gr (Reg) tumors in combination with local microwave hyperthermia (HT) in the background of the introduction of radiomodification hormonal drug testosterone (Testosterone + Region + GT).

Assessment of the effect was performed by measuring tumor volume, i.e. the maximum size of the tumor in three perpendicular directions. The resulting numbers were perennial. The data obtained on the day of exposure was considered as the initial volume (Vo) of the tumors, and the data in the other days of the measurements was defined as (Vt). Dynamic regression and recurrence of the tumor reflects the ratio of Vt and Vo. Determining the value Vt produced three times per week for twenty-six days after exposure. The results of the dynamics of change in the volume of tumors in the control group of animals as well as animals, tumors were subjected to remote gamma-therapy GENUS-5 Gr (Reg), in combination with local microwave hyperthermia (HT), as well as the actions of these agents is s the infusion of testosterone (T) are given in table 1.

Table 2 presents the results of measurements of time (in days) of dorstenia up to the original volume of the tumors in all groups, as well as the doubling time of tumors.

Presented in table 1, 2 materials, it is evident that remote gamma-therapy GENUS-5 Gr leads to a significant inhibition of tumor growth, while the impact of local microwave hyperthermia this effect is slightly increased. Testosterone increases the depth of the regression of tumors after remote gamma-therapy GENUS-5 Gy, and after remote gamma-therapy GENUS-5 Gr tumors in combination with local microwave hyperthermia. Depth regression is most pronounced on the sixth day after remote gamma-therapy. Effect modification lesions tumors hormonal therapy in charge of the experiments is expressed quite definitely. Thus, the modifying effect of testosterone by approximately the same for remote gamma-therapy GENUS-5 Gy and for remote gamma-therapy GENUS-5 Gr tumors in combination with the previous local microwave hyperthermia, suggesting that the enhancing effect of hormonal drugs is mainly due to the modification of the action of the radial component.

The above experimental data are not exhaustive and is provided only to explain the invention and confirm its industrial is romanisti. Specialists in this field can improve and / or implement alternatives within the entity of the present invention, reflected in his description.

Example 1.

Patient 3. The age of 60 years. Diagnosis - local-cell carcinoma of the rectum, Art. IV the results of the evaluation of hormonal status:

Testosterone5.4 nmol/l
Prolactin145 mked/ml
Cortisol100 nmol/l
Luteinizing hormone0.6 U/l
Somatotropic hormone3,9 IU/ml
Insulin4.5 mked/ml

When this limit is:

Testosterone7,0-30 nmol/l
Prolactin35-380 mked/ml
Cortisol77-99 nmol/l
Luteinizing hormone0,5-6,0 U/l
Somatotropic hormone 0,2-3,2 IU/ml
Insulin3,0-17,0 last mked/ml

Patients received treatment of the claimed method.

As a result of treatment marked regression of the tumor, which allowed to perform patient radical surgical treatment (abdomino-perineal the extirpation of the rectum).

The patient was under observation for 2 years. During the observation period data for the progression of cancer has been received.

The proposed method treated 8 male volunteers with inoperable cancer of the rectum. Regression of the tumor was possible in 6 cases, to perform a radical surgical treatment.

1. A method of treating colorectal cancer in men by affecting the tumor remote gamma-therapy GENUS-5 Gy, local microwave hyperthermia and entered vnutriuretrale composite mixture containing sodium alginate and a solution of dimethyl sulfoxide, characterized in that exercise daily administration intramuscularly and by applying onto the skin of the abdomen and chest hormonal drug to achieve sustainable higher levels of the sex hormone in the blood, as a hormonal drug use testosterone for 6-8 h before the session remote gamma-therapy exercise vnutriuretralnami introduction the composite mixture including the hormonal drug, as a hormonal drug use testosterone after 6-8 hours the mixture is removed from the rectum, perform remote gamma-therapy with local microwave hyperthermia.

2. The method according to claim 1, characterized in that an input vnutriuretrale composite mixture contains a hormonal drug, sodium alginate and dimethylsulfoxide at the following ratio of ingredients, wt.%: hormonal drug - 4-10, sodium alginate - 8-12, dimethylsulfoxide - 3-5, distilled water up to 100.



 

Same patents:

Oncotherapy // 2387456

FIELD: medicine.

SUBSTANCE: therapy involves introduction of sonicated human DNA combined with nonhistone protein to the patient with the length of human DNA fragments making 200-6000 pairs of bases, and the ratio of sonicated human DNA/nonhistone protein being 1/0.8. The complex is administered in a dose to ensure the blood concentration of sonicated human DNA 25 ng/ml - 1000 ng/ml.

EFFECT: application of the invention implies oncotherapy ensured by substitution of replacement oncolocus by a DNA fragment with nonmutant allele to form a nucleotide stable complex.

2 cl, 4 tbl, 11 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula Ia: and its pharmaceutically acceptable salt, where: p equals 0 or 1; n assumes values from 1 to 3, q equals 1; R5 is selected from hydrogen, -XNR7R8, pyrimidine-C0-4alkyl, pyridine-C0-4alkyl, phenyl, C3-10cycloalkyl-C0-4alkyl and C3-6heterocycloalkyl-C0-4alkyl, where C3-6heterocycloalkyl is a saturated monocyclic ring system containing the said number of atoms, provided that one or more of the said carbon atoms is substituted with O or NR, where R is hydrogen or C1-4alkyl; R7 and R8 represent C1-4alkyl; R6 denotes hydrogen; or R5 and R6 together with a nitrogen atom to which they are both bonded form morpholine or piperidine; where any piperdine-C0-4alkyl, piperidine-C0-4alkyl or C3-10cycloalkyl-C0-4alkyl of substitute R5 or a combination of radicals R5 and R6 can be optionally substituted with 1-2 radicals which are independently selected from -XNR7R8 and -XOR7, the said phenyl of substitute R5 is substituted with a -XR9 group, the said C3-6heterocycloalkyl-C0-4alkyl of substitute R5 is optionally substituted with a -XOR7 group, where X is a single bond or C1-4alkylene; R7 and R8 are independently selected from hydrogen and C1-4alkyl; R9 is selected from C3-10heterocycloalkyl which is a saturated monocyclic ring system containing the said number of atoms, provided that one or more of the said carbon atoms is substituted with O or NR, where R is as given above; R10 denotes hydrogen; R15 is selected from halogen, C1-6alkyl and C1-6alkoxy; and R16 is selected from halogen, methoxy, nitro, -NR12C(O)R13, -C(O)NR12R12, -NR12R12, -C(O)OR12 and -C(O)NR12R13; each R12 is selected from hydrogen and C1-6alkyl; R13 is selected from phenyl, thienyl, pyrazolyl, pyridinyl or isoxazolyl, where any phenyl, thienyl, pyrazolyl, pyridinyl or isoxazolyl of substitute R13 can be optionally substituted with 1-2 radicals which are independently selected from halogen, C1-6alkyl, halogen-substituted C1-6alkyl, imidazole-C0-4alkyl, C3-10cycloalkyl, C3-10heterocycloalkyl-C0-4alkoxy and C3-10heterocycloalkyl-C0-4alkyl; where the said C3-10heterocycloalkyl-C0-4alkoxy and C3-10heterocycloalkyl-C0-4alkyl each represent a saturated monocyclic ring system containing the said number of atoms, provided that one or more of the said carbon atoms is substituted with O or NR, where R assumes values given above; and the said C3-10heterocycloalkyl-C0-4alkoxy and C3-10heterocycloalkyl-C0-4alkyl can each be optionally substituted with 1 radical independently selected from C1-6alkyl, hydroxyl-substituted C1-6alkyl and NR7R8, where R7 and R8 assume values given above. The invention also relates to pharmaceutical compositions containing the said compounds.

EFFECT: obtaining novel compounds and compositions based on the said compounds which can be used in medicine for treating and preventing diseases or disorders associated with abnormal or uncontrolled kinase activity, particularly diseases or disorders associated with abnormal activity of kinase c-Src, FGFR3, KDR and/or Lck.

12 cl, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and biotechnology and concerns an anticancer drug based on nanoparticles bearing recombinant human tumour necrosis factor alpha. Substance of the invention includes the anticancer drug representing nanoparticles each of which contains a nucleus consisting of polynucleotide complex representing double-helical RNA (dhRNA) - an interferonogenesis inducer, and coated with a layer of spermidine conjugate with polyglucin held by ionic interaction between negative polynucleotide complex and positive spermidine, while recombinant human tumour necrosis factor alpha is covalently bound with activated polyglucin. As double-helical RNA, the anticancer drug contains double-helical RNA of Saccharomyces cerevisiae yeast. Nanoparticles are ball shaped and sized about 50-70 nm; 60-80 molecules of recombinant human TNF-α of cytolytic activity 106 ME/mg of protein and higher, 60-80 molecules of polyglucin and 1000-1300 molecules of spermidine are necessary for one molecule of double-helical RNA of Saccharomyces cerevisiae yeast.

EFFECT: reduced dose of TNF-α and lower toxicity.

5 cl, 5 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to preparation of a plant drug for treating stomach cancer. The drug for treating stomach cancer contains cod-liver oil, badger fat, plant seed blood chosen from the group: pomegranate, hot pepper, fennel and activated coal in the following ratio, wt %: cod-liver oil 28; badger fat 28; seed blood 42; activated coal the rest.

EFFECT: treatment with the declared drug involves activating body defences, resistance ensured by improved functioning of an individual's organs and systems, and targeting the lesion focus.

2 ex

Cancer therapy // 2386442

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely oncology and can be used in mesothelioma treatment. The method consists in monthly subcutaneous introduction to the patient of powdered fibrin solution recovered from the donor's blood clot in a dose 100-600 mg of dry powder per one introduction session.

EFFECT: application of the invention allows for effective cancer therapy by fibrin preparation only without administration of cytostatic agents, radioactive drugs and radioisotopes that ensures reduced complications.

3 dwg, 1 ex

Biomarker // 2385944

FIELD: medicine.

SUBSTANCE: invention describes a biomarker intended for determining sensitivity of proliferative diseases, such as cancer, to mTORs inhibitor combined with a cytotoxic agent, first of all with a cytotoxic agent (CA) that damages or disturb DNA integrity. According to the invention, the biomarker designated as p21 represents cip/kip-family of cyclinkinase inhibitors. Sensitivity or response of the proliferative disease in an individual on treatment with mTOR inhibitor combined with CA is determined by the level of p21 expression after CA treatment and a combination therapy with using CA and mTOR inhibitor. Favorable treatment and sensitivity of disease to the combination therapy is predicted by the absence of expression induction reduced. Besides according to the invention, the biomarker can be used in the method to overcome the CA resistance in the patient treated with CA. That is ensured by evaluating p21 level in a sample, the increasing regulation of p21 expression following CA introduction to the patient, mTOR inhibitor is administered in combination with CA, while lowered expression regulation observed following the combination therapy ensures to continue treatment with mTOR inhibitor with simultaneous or consecutive CA introduction.

EFFECT: application of the invention allows for more accurate prediction of sensitivity of a proliferative diseases in an individual to the combination therapeutic treatment.

4 cl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel substituted quinoline derivatives of general formula (I) in which: m is an integer from 0 to 3; R1 is selected from a group comprising an acylamino group, ester carboxylic group and an alkyl with 1-5 carbon atoms, an optionally substituted hydroxy and a halogen; R2 denotes hydrogen or an alkyl with 1-5 carbon atoms; R3 denotes - C(=X)-A, where A is selected from a group comprising aryl, heteroaryl, heterocyclyl and cycloalkyl, each of which can optionally contain from 1 to 4 substitutes selected from a group comprising an alkyl with 1-4 carbon atoms, an alkoxy with 1-4 carbon atoms, a halogen, hydroxy or nitro, and X denotes oxygen or sulphur; R4 denotes alkylene-heterocyclyl or alkylene-NR7R8, where alkylene is a linear alkylene with 1-4 carbon atoms; R7 and R8 are independently selected from a group comprising hydrogen, an alkyl with 1-4 carbon atoms, arylalkyl, heteroarylalkyl, cycloalkyl or cyclo-alkylalkyl; R5 is selected from a group comprising L-A1, where A1 is selected from a group comprising aryl, heteroaryl, heterocyclyl and cycloalkyl, each of which can optionally contain from 1 to 4 substitutes selected from a group comprising an alkyl with 1-4 carbon atoms, an alkoxy with 1-4 carbon atoms, a halogen, hydroxy and nitro, and where L is selected from a group consisting of oxygen, -NR9, where R9 denotes hydrogen or alkyl; -S(O)q-, where q equals 0, 1 or 2, and an alkylene with 1-5 carbon atoms, optionally substituted with a hydroxy, halogen or acylamino; and R6 is selected from a group comprising an alkyl with 1-5 carbon atoms, an alkenyl with 2-5 carbon atoms, an alkynyl with 2-5 carbon atoms, -CF3, an alkoxy with 1-5 carbon atoms, a halogen and a hydroxy; or its pharmaceutically acceptable salts or esters, as well as to a pharmaceutical composition having anticancer activity or inhibitory effect on mitotic kinesin based on the said compounds, to a method of treating disorders and use of these compounds for making a medicinal agent.

EFFECT: novel compounds which can be useful in treating cancer are obtained and described.

40 cl, 3 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention describes novel derivatives of 2,6-diaminopyridine of formula (I), where R1 is piperidine which is optionally substituted with up to four substitutes independently selected from a group comprising: (a) hydrogen, (b) lower alkyl, (c) lower alkyl substituted with an oxo group or aryl, (d) CO2R7, (e) COR12, (f) C(O)NR13R14, and (g) S(O)nR15; R2 is phenyl which can be substituted with up to four substitutes independently selected from a group comprising: (a) lower alkyl, (b) lower alkyl substituted with a halide or OR10, (c) halide, or (d) OR12; R5 and R6 are independently selected from a group comprising (a) hydrogen and (b) lower alkyl; R7 is selected from a group comprising (a) hydrogen and (b) lower alkyl; R10 is selected from a group comprising (a) lower alkyl, (b) aryl and (c) aryl substituted with a halide or NR5R6; R12 is selected from a group comprising (a) hydrogen and (b) lower alkyl; R13 and R14 are independently selected from a group comprising (a) hydrogen and (b) lower alkyl, R15 is selected from a group comprising (a) aryl, (b) aryl substituted with a halide, CO2R12, SO2R10, COR12, lower alkyl or lower alkyl substituted with a halide, OR12, oxo group, CO2R12, C(O)NR5R6 or NR5R6, (c) heteroaryl, (d) heteroaryl substituted with a halide, CO2R12, SO2R10, COR12, lower alkyl and lower alkyl substituted with a halide, OR12, oxo group, CO2R12, C(O)NR5R6 or NR5R6, (e) NR5R6, (f) lower alkyl, (g) lower alkyl substituted with a halogen, OR12, oxo group, CO2R12, C(O)NR5R6 or NR5R6, (h) a heterocycle and (i) a heterocycle substituted with CO2R12, COR12, SO2R10, lower alkyl, C(O)NR5R6 or NR5R6; n equals 0, 1 or 2; as well as a pharmaceutical composition having inhibitory effect on cyclin-dependant kinase and a method of producing the compound of formula I.

EFFECT: novel compounds which have antiproliferative activity and can be used for treating or curbing cancer are obtained and described.

28 cl, 58 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: invention refers to 3-oxo-28-(N-methylpiperazine)-carbonyl-lup-20(29)-ene of formula (I) which can be used in medicine as a corrective agent for paraneoplastic damages and toxic effects of cytostatic polychemotherapy. .

EFFECT: compound I shows an apparent anticancer activity, reduces severity of pathological changes in tissues caused by paraneoplastic syndromes; in cytostatic polychemotherapy, it exhibits an apparent antioxidant and cytoprotective effect in normal cells of viscera and thereby does not stimulate proliferation and dissemination of a tumour.

8 ex, 8 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: there is described an immunogen for making an immunogenic cancer composition free of DNA-binding function and all domains of a zinc finger, on the basis of polynucleotide coding a nonfunctional mutant form of a related molecule ("brother") of regulator of imprint sites (BORIS) of protein, polypeptide or peptide, containing amino acid sequence presented in the description. The immunogenic cancer composition contains aforementioned immunogen and an adjuvant chosen particularly from cytokine, chemokin, a costimulating molecule. There is described an expression vector containing polynucleotide, coding above-stated protein, e.g., in bacterial systems, mammal systems, in yeast or viral systems. The cancer vaccine under the invention contains polynucleotide (immunogen), additionally the adjuvant and, if necessary, a pharmaceutically acceptable carrier. The invention describes the method for of cancer immunisation of a mammal with using said immunogen on the basis of polynucleotide.

EFFECT: invention allows improving effectiveness of cancer prevention.

28 cl, 7 dwg, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: at the stage of early presentations of posterior aggressive retinopathy of premature newborns not later than the 6th week of a child's life laser coagulation is applied to form a demarcation line or a demarcation axis. The exposure is started from the extreme periphery to the centre in 5-6 lines. The coagulates are distanced to be matched with a coagulate diametre. The laser coagulation is immediately followed with intravitreal introduction of an anticoagulant.

EFFECT: invention provides reliable regression of posterior aggressive retinopathy of premature newborns and following complete absence of clinical evidences of disease activity.

2 cl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, oncology, and can be used for multimodality treatment of locally advanced cervical carcinoma. That is ensured by the three-staged therapy. The first stage involves 2 courses of the systemic polychemotherapy. The second stage is embolisation of uterine arteries from both sides. At the third stage a course of the combined radiotherapy follows. It involves the gamma ray teletherapy in a dynamic mode. The patient is exposed to irradiation from two open opposite fields measured 16×17-19 cm at a single focal dose 4 Gy to a total focal dose 18 Gy. It is followed with the gamma ray teletherapy with fractionating the single focal dose by 2 Gy to the total focal dose 30 Gy. Then a 10-14-day interval is followed with the gamma ray teletherapy from four divided fields measured 6×17-19 cm at the single focal dose 2 Gy to the total focal dose 50 Gy. Intracavitary gamma ray therapy includes fractionating the single dose by 10 Gy to the total focal dose 50 Gy.

EFFECT: method allows optimising treatment of locally advanced cervical carcinoma and improving its clinical effectiveness.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to experimental medicine and aims at normalising antioxidant blood system activity. In acute immobilisation stress, breast region is exposed to tetra-hertz waves at molecular nitrogen oxide radiation and absorption spectrum frequencies 150,176-150,664 GHz and power density ~0.2 mWt/cm2 during 30 minutes.

EFFECT: method allows normalising antioxidant blood system activity in experimental environment.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, oncology, and can be used for treating prostate cancer. Therefore, the treatment is two-staged. The first stage involves gamma therapy with fractionated dose. First three days, the dose is 4 Gy. Then five times a week, the dose is 2 Gy to the total focal dose 38 Gy. In the 4th, 6th, 9th, 11th, 14th days, no more than 60 minutes prior to each session of gamma therapy, radiomodification by transurethral thermotherapy is performed. Herewith radiomodification is preceded with trial catheterisation of urinary bladder and urethral anaesthesia by introduction of 2-4 ml of mixed lidocaine-glycerine. The mixure is prepared at 2.0 of 2% lidocaine and 10.0 of glycerine. Thermotherapy is performed in a radio-frequency range at frequency 40.46 mHz with maximum power 40 Wt and duration of one session 60 minutes. The same procedure is applied for transurethral thermotherapy at the second stage of treatment after a fortnight break. At the second stage, remote gamma therapy is also performed five times a week in a dose 2 Gy to the total focal dose 68 Gy.

EFFECT: method enables adequate anaesthesia during sessions of thermotherapy, prevention of such complications as urethritis, urethral strictures, improves clinical effectiveness for prostate cancer of I, II, III stages.

3 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely minimally invasive interventions, and aims at efficiency control of laser destruction of benign breast growths. It involves ultrasonic examination of breast with recording Doppler blood flow spectrum. It is followed with laser-induced interstitial diode-laser thermotherapy generating real-time ultrasound-aided high-intensity IR laser light. After achieving the therapeutic effect, on the 4th minute focal vascular inversion of arterial blood is recorded as a variation of blood flow direction in arteries, accompanied by increasing peak systolic blood velocity and decreasing peripheral resistance in comparison with the reference values.

EFFECT: method makes it possible to ensure adequate real-time efficiency control of laser destruction of benign breast growths with the absence of radiation exposure of the patient and medical personnel.

4 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely neurology and can be used for treating infantile cerebral paralysis (ICP). The method is implemented as follows: when detecting a mixed infection, there is determining its sensitivity to antibacterial preparations. It is followed with myeloexfusion of bone marrow to recover mononuclear leukocytes; the recovered fraction of mononuclear leukocytes is irradiated with a helium-neon laser light of the power 2.0 mWt during 15 minutes. Further, an etiotropic antibacterial preparation is adsorbed on these mononuclear leukocytes in a daily dosage considering the patient's age and body weight and introduced intravenously. Therapeutic procedure is daily within 5-7 days; additionally hepatoprotectors, immunomodulators and dysbacteriosis preventive agents are administered.

EFFECT: application of the invention allows improving clinical effectiveness in relation to ICP due to the reparation of tissues exposed to infection by the directed antibiotics delivery through hematoencephalic barrier into the centre of neuroinfection.

1 ex

FIELD: medicine.

SUBSTANCE: invention concerns radiobiology. The method consists that in animals irradiated with doses 8-10 Gy during first 4-8 days drinking water is substituted by oral aqueous extract of dried inflorescences Chamaenerion angustifolium in effective amount.

EFFECT: method stimulates increase in cell count of bone marrow, spleen and total leukocytes in venous blood.

3 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: installation contains controlling light dose source of laser radiation, whose light conductor is fastened on support, and device for protection of healthy skin from laser irradiation, fastened with possibility of fixation in definite position, via transitional device, on frontal holder. Device for protection made in form of three parallel flat discs, having general central axis, external discs being rigidly connected to each other on perimetre with formation of blind cavity and with transitional device. Internal disc has smaller than external discs diametre, is fastened on general central axis with possibility of rotation and is divided into equal sectors, in each of which through opening of definite diametre is made. In each of external discs coaxially one above another there is opening in form of sector, whose central angle equals central angle of internal disc sector.

EFFECT: increasing efficiency of treatment of any parts of head and neck due to reliable fixation of device for protection of healthy skin from irradiation above tumour.

4 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: dispersions of photosensibiliser nanoparticles are introduced intravenously. After that tumour is preliminarily irradiated by laser pulses in spectral area of photosensibiliser nanoparticles absorption with pulse energy density not lower than 0.1 J/cm2. After that light irradiation of tumour is carried out in spectral area of absorption of molecular form of photosensibiliser.

EFFECT: method allows to reduce necessary dose of introduced photosensibiliser, reduce concentration of spontaneously formed in healthy organs and tissues molecular form of photosensibiliser.

5 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, oncology, and can be used for treating basaliomas. For this purpose dissection of affected skin portions is performed including healthy tissues within 0.5 cm by means of surgical laser with wavelength 810 nm pulse duration 0.2-0.5 seconds radiating power 15 W. After that 0.1% Radachlorin gel is applied on affected surface in terms 0.2 g per 1 cm2 of surface. 2-hour exposition under light-tight bandage. After gel removal surface is processed by laser light with wavelength 662 nm with light energy dose 200 J/cm2. Exposure is performed without contact. As laser radiation source, diode laser apparatus for photodynamic therapy "LAHTA-MILON" can be used.

EFFECT: method allows to prevent cosmetic defect, post-operation complications due to quick healing of affected area, stop of tumor growth of tissues, reduces method traumatism and number of recurrences.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gynaecology and represents the combination for preparing the medical product, containing Anastrozol, Levonorgestrel and Ethynyl Estradiol, the pharmaceutical composition for endometriosis treatment containing Anastrozol, Levonorgestrel and Ethynyl Estradiol and endometriosis treatment method that involves introduction of Anastrozol, Levonorgestrel and Ethynyl Estradiol.

EFFECT: invention provides effective temporary symptom relief in women with severe endometriosis.

3 cl, 2 tbl

Up!